Turnstone Biologics Company Overview
Turnstone Biologics
About Turnstone Biologics
Turnstone Biologics (NASDAQ:TSBX) is a biotechnology firm dedicated to revolutionizing cancer treatment through the development of innovative oncolytic viral immunotherapies and cancer vaccines. Leveraging cutting-edge science, Turnstone's diverse projects aim to harness the power of the body's immune system to target and destroy cancer cells, offering hope for more effective treatments with fewer side effects. The company is focused on advancing its pipeline of novel therapies through clinical trials, with the objective of achieving breakthroughs in cancer care and improving patient outcomes.
What is Turnstone Biologics known for?
Snapshot
2014
Year founded
80
Employees
La Jolla, United States
Head office
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Turnstone Biologics
- Viral immunotherapies leveraging Maraba virus platform for various cancers.
- Development of novel oncolytic vaccines for solid tumors.
- Collaboration projects for enhancing CAR-T and immune checkpoint inhibitors' efficacy.
- Production of engineered viruses for precision cancer therapy.
- Research on combining viral therapies with existing cancer treatments for synergy.
- Services in biomanufacturing for oncolytic virus-based therapies.
equipe executiva do Turnstone Biologics
- Dr. Sammy J. Farah M.B.A., Ph.D.President, CEO & Director
- Ms. Saryah AzmatConsultant
- Ms. Wendy Worcester CFA, CPAVP, Principal Finance & Accounting Officer
- Dr. David Stojdl Ph.D.Senior Vice President of Research & Discovery
- Dr. Ines Verdon M.D.Senior Vice President of Clinical Development